Valuation: Simulations Plus, Inc.

Market Cap 374M 334M 311M 283M 533M 36.03B 537M 3.76B 1.46B 18.39B 1.4B 1.37B 59.12B P/E 2026 *
44x
P/E 2027 * 40.4x
Enterprise Value 374M 334M 311M 283M 533M 36.03B 537M 3.76B 1.46B 18.39B 1.4B 1.37B 59.12B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 4.34x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 week+0.22%
Current month+0.38%
1 month+0.38%
3 months+0.60%
6 months+54.30%
Current year+1.48%
1 week 18.43
Extreme 18.43
18.5
1 month 18.4
Extreme 18.4
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.1
Extreme 8.1011
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Sell

Executive/Senior Manager

-1,000 0.0050%
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.22%+15.48%-55.86% 374M
+3.35%+0.26%+24.56%+34.69% 242B
+3.34%-1.46%+2.89%+2.38% 150B
+3.71%+0.32%-10.14%+40.03% 138B
-0.47%-3.46%-56.43%-17.75% 61.74B
+2.44%+1.09%+13.18%+22.39% 49.08B
-1.08%-0.90%-21.39%-22.66% 47.43B
+2.09%-0.87%+20.93%+53.39% 47.3B
+3.70%+0.99%-4.33%+41.39% 44.25B
+3.51%+1.52%+34.02%+64.37% 41.78B
Average +2.31%-2.23%+1.88%+16.24% 82.3B
Weighted average by Cap. +3.02%-2.98%+4.07%+24.61%

Financials

2026 *2027 *
Net sales 81.87M 73.04M 68.05M 61.92M 117M 7.88B 117M 822M 320M 4.02B 307M 301M 12.94B 86.26M 76.95M 71.69M 65.24M 123M 8.31B 124M 866M 337M 4.24B 324M 317M 13.63B
Net income 9.53M 8.5M 7.92M 7.21M 13.58M 918M 13.68M 95.74M 37.25M 469M 35.79M 35.02M 1.51B 10.18M 9.08M 8.46M 7.7M 14.5M 981M 14.61M 102M 39.78M 500M 38.22M 37.4M 1.61B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
06/10/26 USD 18.50 0.00% 625,306
02/10/26 USD 18.50 +0.05% 460,260
01/10/26 USD 18.49 +0.33% 865,859
30/09/26 USD 18.43 -0.27% 332,435
29/09/26 USD 18.48 0.00% 137,126
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.50USD
Average target price
17.25USD
Spread / Average Target
-6.76%

Quarterly revenue - Rate of surprise